News and Updates

2006                                      
FDA issued black box warning on warfarin related to bleeding.

2007                                      
FDA updated warfarin prescribing information to include genetics.

2007 April
Iverson Genetic Diagnostics, Inc. establishes headquarters in ISB laboratory.

2008
Iverson develops National Sales Team for the Warfarin Sensitivity and Metabolism Product.

2008 January
Iverson obtains marketing rights for FDA cleared genetic test.

2007 - 2009
FDA cleared 4+ warfarin related gene variant platforms.                 

2009 August
CMS decides not to cover costs of warfarin pharmacogenetic tests unless more clinical data.

2009 September
Iverson establishes MSM lab to enhance turnaround time.

2009 October
WARFARIN Study protocol submitted to CMS.

2010 February
CMS responds to the WARFARIN Study protocol.

2010 March
Members of the WARFARIN Study Steering Committee met with CMS about the WARFARIN Study protocol design.

2010 June
CMS has accepted the WARFARIN protocol.

Many clinical sites are interested and signing up daily.  We are approaching our acceptance target of clinical sites. If interested, please contact us at 866.229.4446.